United States

Akero Therapeutics is a clinical-stage company developing treatments for serious metabolic diseases, including NASH. Their lead product candidate, EFX, regulates metabolism and is being evaluated in a Phase 2b clinical trial for NASH patients. Formerly known as Pippin Pharmaceuticals, the company was incorporated in 2017 and is based in South San Francisco.

Google

Gerente de Producto

Científico de Datos

Akero Therapeutics

Akero Therapeutics Vacantes Abiertas

¿Estás listo para hacer crecer tu carrera? Revisa estas posiciones abiertas en Akero Therapeutics.